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ABSTRACT Tetracyclines, which represent one of the
most commonly used antibiotics for poultry, are known
to be deposited in bones, where they can remain, de-
spite the observation of appropriate withdrawal times.
The aim of the study was to determine the concentra-
tion of oxytretracycline (OTC) residues in the bone and
muscle of chickens, following the oral administration of
a commercially available liquid formulation, and to test
their cytotoxic effects on an in vitro cell culture model.
Seventy-two 1-day-old broiler chickens were randomly
allotted into 2 groups (control and treated animals).
OTC (40 mg/kg BW) was administered via drinking
water during the 1 to 5 and 20 to 25 days of life peri-
ods. At the end of the trial, the birds were slaughtered
and the OTC residues in the target tissues were mea-
sured by means of liquid chromatography (LC) - tan-
dem mass spectrometry (MS/MS). Cytotoxicity was as-
sessed by evaluating the pro-apoptotic effect of the bone
residues on the K562 erythroleukemic line and on the
peripheral blood mononuclear cells (PBMC). In all the
animals, the OTC residues in the muscle were far below
the established MRL of 100 μg/kg. The OTC levels in
the bones of the treated animals were instead found in
the parts per million (ppm) range. Cell cytotoxicity was
assessed by evaluating the pro-apoptotic effect of OTC
bone residues on the haematopoietic cell system. This
in vitro system has revealed a significant pro-apoptotic
effect on both the K562 cell line and PBMC cultures.
This result suggests potential human and animal health
risks due to the entry of tetracycline residues contained
in the bones of treated livestock into the food-chain.
This could be of concern, particularly for canine and fe-
line diets, as meat, bone meal, and poultry by-products
represent some of the main ingredients of pet foods,
especially in the case of dry pet food. Further stud-
ies are needed to define the underlying mechanisms of
cytotoxicity and to evaluate the in vivo toxicological
implications due to the observed in vitro effects.
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INTRODUCTION
In intensive poultry production, environmental con-
ditions often compromise animal health and immune
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responses by encouraging infectious diseases to develop
and spread easily. For this reason, the group-level ther-
apeutic use of antibiotics is very common. The tetra-
cycline class of antimicrobial agents is one of the most
commonly used antibiotics in poultry production be-
cause of its low cost, efficacy, and lack of side effects
(Chopra and Roberts, 2001). Typical antimicrobial reg-
imens used to treat gastrointestinal and respiratory dis-
eases in broiler chickens include oral medication with
oxytetracycline (OTC) for 3 to 5 d. Although OTC was
one of the first tetracycline antibiotics ever produced,
limited information is available on its pharmacokinetics
in avian species (Black, 1977; Dyer, 1989; Serrano et al.,
1999). It has been shown that oral administration re-
sults in low and variable systemic levels of the drug and
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that, among edible tissues, the kidneys and liver con-
tain the highest concentrations (Black, 1977). In order
to avoid the presence of drug residues in animal prod-
ucts and to preserve consumers’ health, the European
Union has established maximum residue levels (MRL)
for OTC in poultry products (European Union, 2010).
The observance of appropriate withdrawal periods for
each licensed veterinary product ensures the presence
of OTC residues below the MRL. However, it is well-
known that tetracyclines are able to deposit and per-
sist in bones because they bind directly to the bone
matrix or through a more complex binding that takes
place between the bone matrix (especially in neonates),
calcium ions, and the 4 rings of the basic tetracycline
structure (Milch et al., 1957). Therefore, it is not sur-
prising that a high incidence of tetracycline residues
has been observed in bones taken from pig carcasses
at slaughter houses (Ku¨hne et al., 2000). According
to the same authors, even the smallest recommended
sub-therapeutical dosage of OTC administered orally
to chickens leads to detectable residues in bones after
the withdrawal of medicated feeds. As a consequence,
the current withdrawal times, which are based on the
detectable levels of drugs dropping below the MRL in
edible tissues, do not seem able to guarantee that bone
tissues are free of drug residues after the administra-
tion of tetracyclines. The toxicological implications of
these residues are still not fully understood. Although
in vitro and in vivo tetracycline cytotoxic effects have
already been described, the exact underlying mecha-
nism has not been identified yet (Fife and Sledge, 1998;
Celik and Eke, 2011).
On the basis of these premises, the aim of the study
was to investigate the concentration of OTC residues
in the bone and muscle of broiler chickens, following
oral administration of a commercially available liquid
formulation, and to test their cytotoxic effects on an in
vitro cell culture model.
MATERIALS AND METHODS
Animals and Housing
The study was supervised by the Department of Vet-
erinary Sciences of the University of Turin (Italy) and
performed in the animal farm of the Department of
Agriculture, Forestry, and Food Science of the Univer-
sity of Turin (Italy). The experimental protocol was
designed according to the guidelines of European and
Italian laws pertaining to the care and use of experi-
mental animals (European directive 86/609/EEC, put
into practice in Italy by Legislative Decree 116/92).
A total of seventy-two 1-day-old male and female
broiler chickens (Ross 708) were randomly allotted into
2 groups (control and treated animals, n = 36) and
raised in floor pens (3 pens/group). Each pen housed
12 chickens of a homogeneous weight and sex ratio.
The birds were fed a commercial organic diet, based
on corn and soybean (Abello FIN-IMM s.r.l., Verzuolo,
CN, Italy), which was formulated to meet or exceed the
requirements recommended by the National Research
Council (1994) and adjusted according to the Ross 708
Broiler nutrition specification (Aviagen, 2014). The ex-
periment was carried out in a 7-m wide × 50-m long ×
7-m high poultry house, equipped with a waterproof
floor and wall, covered completely by tiles, and with
an automatic ventilation system. The chicks were dis-
tributed over 6 pens (3 pens/treatment) that were
1.0-m wide × 1.50-m long. Each pen was furnished with
mixed sawdust and rice hulls as litter. Feeds and drink-
ing water were provided ad libitum for the entire dura-
tion of the trial, until day 35, which corresponded to the
slaughter day. The lighting schedule was 23L:1D dur-
ing the first 3 d, followed by 18L:6D until the slaughter
age. Ambient temperature was kept within the thermo-
neutral zone, and during the first 3 wk, the birds were
heated by means of infrared lamps. The chicks were vac-
cinated at hatching against Newcastle disease, Marek
disease, infectious bronchitis, and coccidiosis. Health
status and mortality were monitored daily during the
entire experimental period. Chicken weight and feed
consumption were recorded at 1, 21, and 35 d life us-
ing a high-precision scale (Sartorius, Signum), and the
feed conversion ratio was calculated accordingly. Weight
gain, ADG, daily feed consumption, and the feed con-
version ratio were calculated for the 1 to 21, 21 to 35,
and 1 to 35 d periods, on a pen basis. Three pens were
assigned to the Control (C) group (i.e., the C group)
and 3 pens were assigned to the OTC group (i.e., the
OTC group); the mode of drug administration is de-
scribed hereafter.
Treatment
Therapeutic treatments were applied, in accordance
with the recommendations of the manufacturer, as far
as the dose concentration, dosing period, and with-
drawal time are concerned. Briefly, OTC (Ossitetraci-
clina liquida 20%, TreI, Reggio Emilia, Italy) was ad-
ministered via drinking water at a dosage of 40 mg/kg
live weight during the 1 to 5 and 20 to 25 d life periods.
The amount of OTC dissolved in water was adjusted
daily on the basis of the water intake and BW gain.
The expected withdrawal time (10 d) was applied be-
tween the last OTC administration and slaughtering.
Slaughtering Procedures and Sample
Collection
At the end of the trial (35 d), 6 chicks/pen, (3 males
and 3 females), were randomly chosen from each pen,
and sacrificed by CO2 gassing followed by neck-cutting.
Immediately after slaughtering, the breast and leg were
deboned, muscle was ground, and a pool was created.
Samples were stored at −20◦C pending analysis. The
bones obtained from the breast and leg deboning (ster-
num, femur, tibia, and fibula) were dried overnight at
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50◦C, broken, cured in an autoclave (Alfa-10-plus) at
121◦C and 1.0 bar over 30 min, dried at 50◦C over the
course of 36 h, and finely ground. Samples were stored
at −20◦C pending analysis.
Quantification of the OTC Residues
Acetonitrile, n-pentane, n-hexane, ethyl acetate, and
methanol HPLC-grade, formic acid, EDTA disodium
salt (Na2EDTA), citric acid, and hydrogen sodium
phosphate were provided by Sigma–Aldrich (Milan,
Italy). The high-purity water was obtained from Milli-
Q purification system (Millipore, Bedford, MA, United
States). A McIlvaine-Na2EDTA buffer 0.1 M was pre-
pared by adding 12.9 g citric acid, 10.9 g hydrogen
sodium phosphate, and 37.18 g EDTANa2 to 1 L Milli-
Q water. The solid-phase extraction C18 cartridges
(3 mL, 200 mg) were from Varian (Walnut, Creek, CA,
United States). The analytical standards of OTC, 4-
epioxytetracycline, and demethylchlortetracycline, used
as internal standard, were provided by Sigma–Aldrich
(Milan, Italy).
Standard stock solutions of OTC, 4-epioxy-
tetracycline, or demethylchlortetracycline were pre-
pared by dissolution in methanol to obtain a final
concentration of 1.0 mg/mL. The standard stock
solutions were stored at −20◦C. The standard solutions
were diluted in methanol to obtain a series of working
standard solutions, which were stored at 4◦C in the
dark.
Samples were prepared according to Oka et al. (1998)
with minor modifications. Briefly, an aliquot of 1.0 g
chicken muscle or 0.5 g ground bone pool was placed in
a centrifuge tube, fortified with the standard solution,
vortex shaken for 30 s, and left for 30 min at room tem-
perature to ensure an appropriate distribution in the
matrix. A volume of 4.0 mL McIlvaine–Na2EDTA 0.1 M
buffer (pH 4) was added, the mixture was vortex shaken
for 15 s and centrifuged at 2,600 rpm for 5 min at 10◦C.
The supernatant was transferred to a clean centrifuge
tube, and the residue was re-extracted with 4.0 mL
McIlvaine–Na2EDTA 0.1 M buffer and centrifuged. The
combined supernatants were degreased with 4.0 mL
n-pentane and centrifuged at 2,600 rpm for 15 min at
10oC. The aqueous layer was loaded into a solid-phase
extraction C18 cartridge, which had previously been ac-
tivated with methanol and Milli-Q water. After sample
loading, the solid-phase extraction C18 cartridge was
washed with Milli-Q water. The analytes were eluted
with a mixture of ethyl acetate and methanol (95:5).
The solvent was removed under a 40◦C stream of ni-
trogen, and the residue was dissolved in 100 μL mobile
phase. An aliquot (10 μL) was injected into the liq-
uid chromatography–electrospray interface (ESI)–mass
spectrometry (MS)/MS system.
Analyses were performed with a 1,200-L Varian liq-
uid chromatography–MS/MS triple quadrupole (Wal-
nut, Creek, CA, United States). The mass spectrometer
was equipped with an ESI, operating in the positive
mode. The HPLC was equipped with 2 mobile-phase
pumps (ProStar 210), a degassit on line, an autosam-
pler (ProStar 410), and a column thermostat. The ESI
interface was calibrated using a polypropylene glycol so-
lution, and the ESI parameters were optimized for each
analyte by direct infusion of the individual standard
solution into the mass spectrometer.
The mass spectrometer parameters were: needle
5,000 V, shield 600 V, housing 50oC, capillary voltage
50 V, and detector voltage 1,500 V. High-purity nitro-
gen was used at 25 psi as nebulizer gas and at 19 psi
and 360oC as drying gas. High-purity argon was used
as the collision gas at 2.0 mTorr. The mass spectrome-
ter was operated at selective reaction monitoring mode
to confirm the identity of the analytes in the samples
by selecting specific precursor-to-product ions for each
analyte and by selecting the most abundant transition
for the quantification.
Separations were conducted using a Pursuit C18
(100 × 2.0 mm inner diameter, 5 μm) column with a
Polaris C18 (2.0 mm, 3 μm) guard column Varian (Wal-
nut, Creek, CA, United States) at 25◦C. Solvent A, the
mobile-phase solvent, was water 0.1% formic acid, while
Solvent B was acetonitrile 0.1% formic acid. The mo-
bile phase was delivered to the liquid chromatography
column at a flow rate of 0.3 mL/min. A gradient elution
was performed: 0 to 3 min 10% B; 3.1 to 5 min 75% B;
5.1 to 15 min 10% B.
Calibration curves were prepared for both tissues,
and good linearity was achieved over the tested
concentration ranges (r2 > 0.99 and goodness-of-
fit<10%). The limits of detection for both OTC and
4-epioxytetracycline in the muscle and bones were 0.5
and 4.5 μg/kg, respectively. The within-day precision
and accuracy fell within the range of −20 to +10%.
The analyses were performed in triplicate.
Bone Residue Cytotoxic Evaluation
In order to test the potential cytotoxic role of OTC,
2 different conditioned cell culture media were used as
providers of OTC residues. Briefly, to obtain a cell cul-
ture medium (CCM), 10 mL RPMI 1640 cell culture
medium was incubated and constantly shaken for 48 h
at 37◦C with 1 g ground bone (sterilized by autoclav-
ing at 121◦C in a steam pressure of 2 atm for 10 min)
from chickens reared in the presence (OTC–CCM) or in
the absence (C–CCM) of treatments with OTC (see the
C-group and OTC-group in the Animals and Housing
section). After incubation, the CCMs were recovered
and filtered through 0.20-μm syringe filters (Sartorius
Stedim Biotech, Goettingen, Germany) to remove any
residual ground bone particles and microbial contami-
nation. The CCMs were then diluted at 1: 1, 1: 2, 1:
4, 1: 8, and 1:16 ratios with an absolute RPMI 1640
growth medium, and the resulting mixtures were incu-
bated with 5×105 cells/ml for 48 h at 37◦C and 5% CO2
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in a cell incubator (Thermo Scientific Heraeus, United
States). The effect of OTC alone was evaluated by in-
cubating the drug (2 μg/mL), as described above. Fur-
thermore, 200 μM hydrogen peroxide (H2O2) was used
as a standard positive control of apoptosis in the 5×105
cells/mL culture for 2 h at 37◦C, 5% CO2.
The used cells were the K562 erythroleukemic line
(Carbone et al., 1996) or the peripheral blood mononu-
clear cells (PBMC) from venous blood of healthy hu-
man donors (Terrazzano et al., 2007). The PBMCs were
obtained by centrifugation on Lymphoprep (Nycomed
Pharma) gradients of healthy donor buffy coats ob-
tained from the Blood Bank of the Medical School of
the Federico II University of Naples, as previously de-
scribed (Terrazzano et al., 2007).
Apoptosis was assessed by staining of the cell
membrane-exposed phosphatidylserine with fluorescein
isothiocyanate-conjugated Annexin V, according to the
manufacturer’s instructions (BD Pharmingen), and as
previously described (De Vitis et al., 2011). Samples
were analyzed by means of flow cytometry, using a
fluorescence-activated cell sorting Calibur (Beckman
Instruments, Fullerton, CA, United States), equipped
with CellQuest Analysis Software. The fluorescence-
activated cell sorting analysis was based on Annexin
V staining, and was conducted to evaluate the fluores-
cence intensity of the staining or the percentage of cells
positive to Annexin V so as to have 2 measurements of
the cells undergoing apoptosis.
Statistical Analysis
The statistical analysis for the growth performance
parameters was performed with SPSS 17 for Windows
(SPSS, 2008). The experimental unit was the pen. Be-
fore testing for group differences, normality of data dis-
tribution and homogeneity of variances were assessed
using the Shapiro–Wilk test and the Levene test, re-
spectively. Growth performance data from the C-group
and OTC-group were compared by means of the Stu-
dent’s t-test. Results were considered statistically sig-
nificant for P < 0.05. A statistical trend was consid-
ered for P < 0.20. The results are presented as mean
values ± SD.
The analysis pertaining to the pro-apoptotic effect
was performed using the Mann–Whitney test, and the
results were considered significant when P < 0.05.
RESULTS
The birds remained healthy for the whole period, no
signs of illness were observed, and the mortality rate
was zero for both groups. Growth performance was not
influenced by the treatment (Table 1), and a positive
numerical trend was observed for the OTC group for
the final individual BW (day 35), ADG (1 to 35 d),
weight gain (1 to 35 d), and feed consumption over the
21 to 35 d period.
Table 1. Growth performance parameters in control animals
and in broiler chickens treated with oxytetracycline (OTC)
(mean values ± SD, Student’s t test, n = 3).
Control group OTC group P-value
Growth performance
Mortality rate (%) - - -
Individual BW (g)
d 1 42.3 ± 1.2 42.1 ± 0.9 0.805
d 21 834.5 ± 15.7 867.1 ± 57.0 0.395
d 35 1,729.2 ± 11.2 1,771.89 ± 11.2 0.155
ADG (g)
1 to 21 d 37.7 ± 0.7 39.3 ± 2.8 0.395
21 to 35 d 63.9 ± 1.5 64.6 ± 2.0 0.646
1 to 35 d 48.2 ± 0.3 49.4 ± 1.2 0.160
Weight gain (g)
1 to 21 d 792.3 ± 14.6 825.0 ± 57.8 0.395
21 to 35 d 894.7 ± 20.9 904.8 ± 28.6 0.646
1 to 35 d 1,686.9 ± 11.6 1,729.8 ± 41.5 0.160
Daily feed consumption (g)
1 to 21 d 59.8 ± 3.5 60.3 ± 5.3 0.898
21 to 35 d 112.1 ± 2.0 115.8 ± 1.6 0.068
1 to 35 d 80.7 ± 2.8 82.5 ± 3.1 0.503
Feed conversion ratio
1 to 21 d 1.58 ± 0.06 1.53 ± 0.04 0.324
21 to 35 d 1.76 ± 0.06 1.79 ± 0.05 0.461
1 to 35 d 1.67 ± 0.06 1.67 ± 0.04 0.889
Table 2. Oxytetracycline (OTC) concentrations (μg/kg),
expressed as the sum of the parent drug and 4-epimer, in
the bone and muscle of control and treated broiler chickens
(μg/kg on DM basis, mean values ± SD, n = 3).
Control group OTC group
Muscle <Limit of detection 12.3 ± 6.9
Bone <Limit of detection 1,286.3 ± 256.6
As shown in Table 2, the concentrations of OTC, ex-
pressed as the sum of the parent drug and its 4-epimer,
were far below the established MRL (100 μg/kg) in the
muscle of the treated birds. On the other hand, about
100-fold higher levels were measured in the bones. Nei-
ther the muscle nor the bone samples showed measur-
able concentrations of the drug in the control birds.
Figure 1 reports data from one representative exper-
iment for apoptosis detection in the K562 cell line, in
terms of peak overlay (Panel A) and individual peaks
(Panel B). Forty-eight h incubation with OTC–CCM
(ratio 1:2) (Peak 3) induced a significant increase in
Annexin V staining, compared to the cell culture con-
dition in the medium alone (Peak 2), which represents
the basal level of the apoptosis that occurs in the K562
cell line without any incubation of CCM. Therefore,
OTC–CCM seems able to induce apoptosis in the K562
cell line. C–CCM, instead, only induced slight Annexin
V staining (Peak 4) at the same ratio. These results
point out that C–CCM did not affect cell viability
to any great extent. Interestingly, similar OTC–CCM
and C–CCM effects were observed when PBMC was
used instead of the K562 cell lines (Figure 2). The
overall analysis of all the experiments suggest that a
48-h incubation with OTC–CCM induces significant
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Figure 1. Apoptosis induction evaluated as fluorescence intensity
of fluorescein isothiocyanate–Annexin V-staining in one representative
experiment. The upper panel refers to the overlay of all the fluorescence
peaks in the different conditions for the K562 cell line cultures. The
lower panels represent the fluorescence peaks for each cell condition.
The x-axis shows the fluorescence intensity of Annexin V binding on
a logarithmic scale. The amplitude of the apoptosis induction is pro-
portional to the right sliding of the peak on the x-axis towards higher
values of fluorescence for Annexin-staining (to facilitate the reader’s
interpretation: Peak 1 is the one that shows the lowest intensity, while
Peak 6 represents the peak at the highest intensity in the figure). In all
the panels, the peaks correspond to the following different K562 cell
culture conditions: 1 = in a growth medium alone without Annexin
V staining, as a control of the cell natural fluorescence background;
2 = in a growth medium with Annexin V staining, as a control of
the apoptosis that occurs in the K562 cell line maintained in a cul-
ture without any other incubation; 3 and 4 = peaks that represent the
growth medium with the addition of a conditioned cell culture medium
obtained from the ground bone of chickens reared in the presence
[3 = oxytetracycline (OTC)–cell culture medium (CCM)] or in the
absence [4 = control (C)–CCM] of a treatment with oxytetracycline,
at a diluition of 1:2, stained with Annexin V; 4 = in a growth
medium with the addition of C–CCM, at a diluition of 1:2, stained
with Annexin V; 5 = in a growth medium with the addition of
2 μg/mL OTC, stained with Annexin V; 6 = in a medium with the
addition of 100 μM H2O2, stained with Annexin V. The medium vol-
umes for the different cell cultures were the same. See the Material
and Methods section for the Annexin V staining.
increases in the percentage of cells undergoing apoptosis
in both K562 and PBMC cell cultures (Figure 2, Panels
A and B, respectively). The effect was observed to be
significant at ratios of 1:2, 1:4, and 1:8 (P < 0.05), but
not at the ratio of 1:16. The increase was also statisti-
cally significant after 24 h at the ratios of 1:2 and 1:4,
but was only slightly detectable after 8 and 12 h incuba-
tion (data not shown). It should be noted that the incu-
bation with 2 μg/mL pure OTC elicited similar effects
on apoptosis to those obtained with OTC–CCM. Fur-
thermore, the OTC–CCM and pure-OTC effects were
quite similar to those elicited through the use of H2O2,
which was used as a standard control of apoptosis in-
duction. Despite the fact that apoptosis induction was
evident, even after culture incubation with C–CCM at
a ratio of 1:2 (P < 0.05), the increase was significantly
lower than that obtained with OTC–CCM 1:2 (P <
0.05). It should be pointed out that CCM was used in-
stead of direct incubation with ground bone, since the
latter showed an extensive cytotoxic effect, which was
probably due to direct contact with cells and oxygen
subtraction from the system ascribable to the volume
occupancy of the same ground particles in the culture
medium (data not shown).
DISCUSSION
Growth performance resulted to be within the range
described in the Ross 708 broiler performance objec-
tives (Aviagen, 2014), thus confirming that appropriate
animal care and welfare conditions had been maintained
throughout the study. The lack of influence of OTC on
the growth performance parameters was an expected
result as the drug had been administered at a thera-
peutic dosage regimen rather than for growth promot-
ing purposes. Nevertheless, it cannot be excluded that
an antibacterial action contributed to the positive trend
of the BW and weight gain (Butaye et al., 2003).
Our findings confirm that the bones of broiler chick-
ens treated with therapeutic dosages of oral OTC
contain considerable amounts of OTC residues. The
finding agrees with those of previous studies, thus
demonstrating that bone represents a target tissue for
tetracycline localization (Milch et al., 1957; Buyske
et al., 1960; Ku¨hne et al., 2000). The incidence of tetra-
cycline antibiotic residues in the bones of slaughtered
animals seems to vary from 18.8 to 100%, depending
on the species. In a study performed by Ku¨hne et al.
(2000), the bones of chickens treated for 10 d with
low oral dosages of OTC still contained detectable lev-
els of the drug after a withdrawal time of 15 d. In-
terestingly, in the present study, the concentrations of
OTC were below the MRL set by the European Com-
munity (100 μg/kg) in all the muscle samples. Simi-
lar results have been obtained in turkeys, in which the
existence of a correlation between the percentage of pos-
itive results in the kidneys and liver and that in the
bones has been pointed out (Ku¨hne and Mitzscherling,
2003).
In the present study, CCM containing OTC residues
induced a significant pro-apoptotic effect in both the
K562 and PBMC cell cultures. It is worth noting that if
one considers the CCM as a source of OTC, this in vitro
system represents a useful model to test the cytotoxic
effects of this drug.
A great deal of evidence supports the in vitro and in
vivo cytotoxicity of tetracyclines (van den Bogert et al.,
1981; Shao and Feng, 2013; Chi et al., 2014). Several
possible mechanisms have been suggested, including
the inhibition of mitochondrial protein synthesis and of
the antioxidant defense system (van den Bogert et al.,
 at U
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Figure 2. Apoptosis induction measured as a percentage of cells positive for the fluorescein isothiocyanate–Annexin V binding in the K562
cell line culture (Panel A) and of PBMC (Panel B). The graph bar-columns represent the mean values of the percentage of cells undergoing
apoptosis in all the performed experiments. The different cell incubations and conditioned CCM dilutions are indicated on the x-axis. The
abbreviations indicate the growth medium with the addition of a conditioned CCM obtained from the ground bone of chickens reared in the
presence [oxytetracycline (OTC)–CCM] or in the absence [control (C)-CCM] of a treatment with OTC, a growth medium with the addition of
2 μg/mL OTC, or with 100 μM H2O2. All the cell cultures were stained with Annexin V (see the Material and Methods section). It should be
noted that the bar-column of the medium alone indicates incubation in a growth medium with Annexin V staining, which has been used as a
control of the apoptosis that occurs in the cells when in a culture without any other incubation is maintained. The statistical significance is
indicated with an asterisk for each of the pairs of columns placed under the horizontal square brackets for the coupled-comparison.
1981; Chi et al., 2014). Moreover, the in vitro effects
of tetracyclines have been related to the inhibition of
lymphocyte proliferation and the negative modula-
tion of neutrophil phagocytic functions (Thong and
Ferrante, 1980).
As far as PBMC cell cultures are concerned, the ef-
fects of OTC–CCM appear to be dose-dependent, and
comparable with that of hydrogen peroxide at a dilu-
tion ratio of 1:2. The effect of pure OTC on inducing
apoptosis also appears to be rather relevant, since there
has been no definitive observation on the toxic effects of
this compound on mammalian cells and, in particular,
on humans.
Although a threshold for OTC in vitro toxicity could
not be established, the most interesting result is that
OTC residues in the bones of slaughtered animals main-
tain cytotoxic effects, in spite of mechanical and ther-
mal treatments. In fact, the possible toxicological risks
depend on the degree of biological activity maintained
by the drug residues in fresh raw materials or follow-
ing feed processing. Meat, bone meal, and poultry by-
products are the main ingredients of pet foods, espe-
cially in the case of dry pet food. For the latter, the
most frequently used processing technology to produce
canine and feline diets or dinner ingredients is extru-
sion. The extrusion process usually involves the ap-
plication of both relatively high temperatures (80 to
200◦C) and short residence times (10 to 250 s) (Serrano
and Agroturia, 1996). The thermal stability of tetra-
cycline antibiotics in animal food products has been
the subject of different studies (Ibrahim and Moats,
1994; Hassani et al., 2008). The variety of methodolo-
gies employed in the heat inactivation experiments and
in the detection of the antibiotic residual concentrations
could explain the differences in the results. However,
according to Hassani et al. (2008), low-temperature–
long-time treatments (conventional sterilization) could
destroy >98% of the initial concentration of tetracy-
cline residues, but high-temperature-short-time treat-
ments would leave the residues in the 50 to 90% range
unaltered. Finally, heat stability depends on the type
of matrix. Although it is assumed that tetracyclines
are not very heat-resistant, residues in bones seem to
be more stable (Honikel et al., 1978). When consid-
ering an intermediate product from a rendering plant
mixed with bone splinters containing bound tetracy-
cline residues, a complete destruction during a heat
treatment at 133◦C for up to 45 min could not be
demonstrated (Ku¨hne et al., 2001). It should be noted
that most heat stability studies have evaluated the
degradation of parent drugs without considering the
possible formation of breakdown products endowed
with toxic effects. Little is known about the breakdown
products formed from tetracycline and OTC during
heat treatments (Grataco´s-Cubars´ı et al., 2007; Ku¨hne
et al., 2001). Therefore, it cannot be excluded that the
cytotoxic effects observed on the K562 and PBM cells
can be ascribed to different compounds from OTC.
Besides the fact that it is necessary to be cautious in
drawing conclusions about in vivo toxicological impli-
cations due to the observed in vitro cytotoxic effects,
it cannot be excluded that OTC residues in the bones
of treated chickens can induce biological responses in
pets and human consumers. Interestingly, higher OTC
and doxycycline serum levels than the safety limits have
been observed in gym-trained subjects with food in-
tolerance symptoms (Di Cerbo et al., 2014). The au-
thors speculated that tetracycline antibiotic residues
transferred to the final consumers could act as hap-
tens and induce specific intolerance to a wide variety
 at U
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of food. Further studies are needed to confirm this
hypothesis.
Following oral treatment with therapeutic doses of
OTC, residues in the parts per million range accumu-
late in the bones of treated animals. Although little
is known about the biological activity of the residues
contained in target organs of slaughtered animals, the
present findings suggest in vitro pro-apoptotic effects
on normal and cancer cells of humans. Further stud-
ies are needed to define the mechanisms responsible for
the cytotoxic effect. Potential human and animal health
risks, due to the entry of tetracycline residues contained
in the bones of treated livestock into the food chain,
should not be underestimated.
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